Targeting the microenvironment in ovarian cancer
Mené en Italie sur 74 patientes atteintes d'un cancer ovarien avancé résistant aux sels de platine, cet essai randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de pazopanib au paclitaxel
The tumour microenvironment has a complex interaction with carcinogenesis and progression in ovarian cancer. Targeting cancer cells as well as key components of the tumour microenvironment might be synergistic and improve clinical outcomes, as shown by positive trials of anti-angiogenic treatments in conjunction with systemic chemotherapy. Four phase 3 studies have shown that bevacizumab administered concomitantly with chemotherapy followed by maintenance in an adjuvant or recurrence setting improves progression-free survival relative to chemotherapy alone.